Objectives
After participating in this educational activity, attendees should be able to:
1|Recognize best practices for inpatient handling, medication reconciliation, and mitigation of U-500 insulin dosing errors
2|Identify clinical scenarios in which U-500 insulin is appropriate for management of severe insulin resistance in type 2 diabetes
3|Differentiate concentrated regular U-500 insulin from U-100 insulin regarding pharmacokinetics, device options, and safety considerations
4|Apply evidence-based strategies to convert and titrate U-100 regimens to U-500 insulin using BID or TID dosing methods
Presenter(s):
Brittney Brzoska, PharmD
Brittney Brzoska, PharmD
PGY2 Ambulatory Care Pharmacy Resident
Baystate Medical Center
| Name | Role | Financial Relationship Disclosures | Discussion of Unlabeled/Unapproved Uses of Drugs/Devices in Presentation? |
|---|---|---|---|
| Brittney Brzoska, PharmD | Speaker/Author | No relevant relationships with ineligible companies to disclose | No |
Session date:
11/17/2025 - 2:00pm to 3:00pm EST
Add to calendar:
- 1.00 ACPE Contact Hours
- 1.00 ACPE Technician contact hours
Facebook
X
LinkedIn
Forward